
Katherine C Dallow MD MPH, CPE (She/her)
Seasoned Physician Executive | Value Based Care | Population Health | Medical Policy | Quality & Accreditation | Utilization Management | Talent Management & Team Building | Executive Leadership
Join to view full profile
10 Powder House RdDover, MA 02030
Dr. Dallow is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Katherine Dallow, MD, is an internal medicine specialist based in Dover, MA. Dr. Dallow completed a residency in internal medicine at Beth Israel Deaconess Medical Center and holds an MPH in Health Policy and Management from Harvard School of Public Health. Dr. Dallow currently serves as Chief Medical Officer of WNS-HealthHelp and has held various leadership roles, including VP and Executive Medical Director at Carelon Medical Benefits Management and previous medical director positions at Blue Cross Blue Shield. Additionally, Dr. Dallow has an academic background with publications in noted medical journals and has been recognized with the Alpha Omega Alpha honor in 2000.
Education & Training
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2000 - 2003
Harvard T.H. Chan School of Public HealthMPH, Health Policy and Management, 1995 - 2000
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2000
Certifications & Licensure
RI State Medical License 2016 - 2028
MA State Medical License 2002 - 2027
MO State Medical License 2026 - 2027
American Board of Internal Medicine Internal Medicine- American Association for Physician LeadershipCertified Physician Executive (CPE)
Awards, Honors, & Recognition
- Alpha Omega Alpha 2000
Publications & Presentations
PubMed
- 92 citationsUse of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostateAnthony L. Zietman, M.K. Tibbs, K.C. Dallow, Christina T. Smith, Alex F. Althausen
Radiotherapy and Oncology. 1996-08-01 - 77 citationsImplications of prostate micrometastases in pelvic lymph nodes: an archival tissue study.Robert A. Edelstein, Anthony L. Zietman, Antonio de las Morenas, Robert J. Krane, Richard K. Babayan
Urology. 1996-03-01 - 37 citationsTime to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized diseaseAnthony L. Zietman, K.C. Dallow, Patricia A. McManus, Niall M. Heney, William U. Shipley
Urology. 1996-02-01
Press Mentions
- The Pandemic Ushered in 'A New Era of Medicine'. These Telehealth Trends Are Likely Here to StayMarch 22nd, 2021
- Health Insurance Provider Actions Concerning the COVID-19 VaccinesMarch 16th, 2021
Blue Cross Blue Shield of Massachusetts Releases COVID-19 Vaccination Public Service Announcement VideoJanuary 25th, 2021
Professional Memberships
- Member
External Links
- LinkedINhttp://www.linkedin.com/in/katherine-dallow-md-mph
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: